＜＜BACK

NEXT＞＞

Vol. 52 Suppl. 2 2024

SYMPOSIUM：The 15th Academic Meetings

SCT Trial of the Year 2023: From JSCTR-SCT Joint Symposium

T. Kato

Jpn Pharmacol Ther 2024; 52(s2): s59-60.

---

Report on the Workshop “Expectations for the Metaverse as a New Connecting Space:
Enhancement of Communication among Various Stakeholders Involved in Clinical Trials”

N. Kamiyama

Jpn Pharmacol Ther 2024; 52(s2): s61-65.

---

Hold a Metaverse Society and a Real Society at the Same Time

H. Matsuyama

Jpn Pharmacol Ther 2024; 52(s2): s66-71.

---

Exemption of Informed Consent in Research Regulations:
In the Context of Current Regulatory Descriptions

T. Watanabe

Jpn Pharmacol Ther 2024; 52(s2): s72-73.

---

A Survey of the General Population’s Attitude
towards Clinical Trial Participation in Emergency Situations:
What Decision Would You Like to Make?

E. Arita，R. Takehira，Y. Masamura，M. Fukuda-Doi

Jpn Pharmacol Ther 2024; 52(s2): s74-79.**

---

The Future of Healthcare and Clinical Trials Utilizing AI

K. Asano

Jpn Pharmacol Ther 2024; 52(s2): s80-81.

---

Exploring International Models of Ethics Review Committees for Best Practices

K. Takashima

Jpn Pharmacol Ther 2024; 52(s2): s82-83.

---

Exploring Patient and Public Involvement （PPI）from the Patient's Perspectives

K. Takashima

Jpn Pharmacol Ther 2024; 52(s2): s84-85.

■ REVIEW ARTICLE

Pragmatic Trials :NIH Pragmatic Trials Collaboratory Activities and
Overseas Trends for Use in Regulatory Decision Making

H. Nakamura, M. Okamoto, S. Ueno, T. Miyaji, K. Hatano, H. Oi, T. Yamaguchi

Jpn Pharmacol Ther 2024; 52(s2): s86-92.*